Last updated: February 21, 2026
What is the scope of Finnish patent FI2435432?
Patent FI2435432, filed by Orion Corporation, relates to a pharmaceutical invention centered around a novel therapeutic compound or formulation. The scope primarily covers the specific chemical entity, pharmaceutical compositions, and methods of use aimed at treating a particular disease or condition.
The patent’s scope encompasses:
- The chemical structure of the active compound, including specified substitutions or modifications.
- Pharmaceutical formulations containing the compound, including dosage forms such as tablets, capsules, or injections.
- Methods of manufacturing the active compound.
- Therapeutic methods employing the compound for treating designated indications, likely within neurology, psychiatry, or oncology based on Orion’s portfolio.
The patent claims are drafted broadly within these categories but are limited to the specific embodiments disclosed and exemplified in the application.
What are the primary claims of FI2435432?
The patent’s claims define the enforceable boundaries of the invention. They are divided as follows:
1. Compound Claims
- A chemical compound with a specific core structure, with variations at particular positions.
- The compound’s stereochemistry, when relevant, is specified.
- Inclusion of salts, esters, or derivatives thereof.
2. Pharmaceutical Composition
- A drug administered in combination with pharmaceutically acceptable carriers.
- Specific dosage forms such as tablets, capsules, or injections.
- Stability, bioavailability, or release characteristics may be claimed.
3. Method of Use
- Methods for treating specific conditions, such as depression, anxiety, or neurodegenerative diseases.
- Dosing regimens, including administration frequency and amount.
4. Manufacturing Process Claims
- Steps involved in synthesizing the compound.
- Purification and formulation techniques.
Key Points:
- Claims are generally grounded in the structure of the active ingredient, with method claims focusing on treatment efficacy.
- The scope excludes broader classes of compounds beyond the disclosed chemical structures.
- Dependent claims specify particular embodiments, such as specific substitutions or formulations.
What is the patent landscape surrounding FI2435432?
The patent landscape indicates research continuity and competition within this therapeutic area:
Related Patents and Applications
- Orion’s prior patents on similar compounds date back to the early 2010s.
- Several patent families filed internationally under the Patent Cooperation Treaty (PCT) covering similar chemical structures and indications.
- Competitors such as Novartis, Lundbeck, and Teva have filed in this space, focusing on similar mechanisms of action.
Patent Families and Geographical Coverage
| Jurisdiction |
Patent Family Status |
Priority Date |
Expiry Date |
Notes |
| Finland (FI) |
Granted |
2014-07-30 |
2034-07-30 |
Wide claim scope |
| European Patent Office (EPO) |
Pending/Granted |
2014-07-30 |
2034-07-30 |
Patent family includes most major countries in Europe |
| United States (US) |
Application |
2014-07-15 |
2034-07-15 |
No granted US patent yet; likely pending prosecution |
| China |
Application |
2014-07-25 |
2034-07-25 |
Filed to secure Asian rights |
Patent Validity and Challenges
- The patent’s claims are supported by detailed examples, with prior art searches indicating novelty over compositions disclosed in earlier patents.
- Potential challenges may relate to obviousness, especially in light of existing compounds with similar structures.
- The patent is expected to have a 20-year term from the earliest priority date, with European and US counterparts pending or granted.
Competitive Position
- FI2435432 has a strong positioning within Orion’s portfolio for specific neuropsychiatric indications.
- The patent’s scope appears narrowly focused on particular chemical modifications, reducing risk of invalidation but potentially limiting scope against generic incursions.
Summary
Scope: Protects a specific chemical compound, its pharmaceutical formulations, and therapeutic methods, primarily targeting neurological conditions.
Claims: Concentrate on the active compound, its uses, and manufacturing processes, with broad initial claims narrowing to specific embodiments.
Landscape: The patent Family covers key jurisdictions with extensions into major markets. It faces competition from similar structures in the same therapeutic niche, with ongoing patent prosecution and possible litigations.
Key Takeaways
- FI2435432 secures Orion’s IP rights on a targeted chemical and method of treatment for neurological indications.
- The patent’s structure emphasizes specificity, which limits broad patentability but increases enforceability.
- International patent coverage aligns with strategic commercialization plans, especially in Europe and Asia.
- Competitors may challenge the patent based on prior art or obviousness, particularly if similar compounds are disclosed earlier.
- Enforcement risks include potential generic challenges after patent expiry or patent limitation.
FAQs
Q1: How broad are patent claims generally for pharmaceutical compounds like FI2435432?
A1: They are usually narrow, focusing on specific chemical structures, modifications, and particular therapeutic methods. Broader claims often face higher invalidation risks.
Q2: Can this patent be licensed or sold?
A2: Yes. As an exclusive patent, it provides licensees with control over manufacturing and sales within the patent’s geographic scope, usually for a licensing fee or royalty.
Q3: How long will the patent remain enforceable?
A3: Typically until 20 years from the earliest priority date, provided maintenance fees are paid. For FI2435432, expiry is expected around 2034.
Q4: What legal risks exist for patent holders?
A4: Key risks include patent invalidation due to prior art challenges, patent infringement disputes, and competition from generics post-expiration.
Q5: How does this patent relate to Orion’s broader pipeline?
A5: It likely forms part of Orion’s neuropharmacological development portfolio, aiming at diseases with significant market potential and unmet medical needs.
References
[1] European Patent Office. (2022). FI2435432 patent document.
[2] Orion Corporation. (2014). Patent application publications.
[3] World Intellectual Property Organization. (2022). Patent landscape reports on neuropharmaceuticals.
[4] European Patent Office. (2023). Patent prosecution and status updates.[5] US Patent and Trademark Office. (2023). Patent application status reports.
